Generic Ozempic Is Arriving. The Real Test Is Whether Patients Can Afford It

For millions of people, the most important semaglutide breakthrough may not be a new medical effect. It may be competition. Generic versions are entering Canada, creating an early real-world test of whether one of the world’s most talked-about medicines can become meaningfully more affordable.

KEY NUMBER
At a modelled 70% price reduction, semaglutide alone reached a cost-effectiveness ratio of C$22,700 per quality-adjusted life year compared with standard care excluding SGLT2 inhibitors.

Why Canada has become the test market

Semaglutide belongs to a class of medicines known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is used under different brand names and indications for type 2 diabetes and chronic weight management. The drugs can also reduce cardiovascular and kidney risks in appropriate patients, but their price has limited coverage and access.

Canadian exclusivity for semaglutide expired in January 2026, years before comparable generic competition is expected in some other major markets. Health Canada approved its first generic diabetes version in April and its first generic weight-management version in June. More applications remain under review.

That makes Canada more than a national story. Health systems, manufacturers and patients elsewhere will be watching what happens to prices, supply and prescribing when multiple approved competitors enter a high-demand market.

What the new study calculated

Researchers used a health-economic microsimulation to project lifetime costs, quality-adjusted life years and cardiovascular and kidney complications for people with type 2 diabetes at high cardiorenal risk. They compared several treatment strategies across possible generic semaglutide prices.

At a 60% reduction from the 2025 price paid by Quebec’s public drug plan, the model suggested that combining a GLP-1 medicine with an SGLT2 inhibitor could become the preferred strategy for the relevant patient group. At a 70% reduction, semaglutide alone became cost-effective against standard care that did not include an SGLT2 inhibitor, while dual therapy was cost-effective compared with an SGLT2 inhibitor alone.

The analysis estimates that 1.3 million to 2.1 million people in Canada may meet relevant eligibility criteria. At pre-generic prices, supplying GLP-1 medicines to all indicated patients could cost roughly C$3.35 billion to C$5.31 billion annually. Even a cheaper medicine therefore remains a major budget decision when the eligible population is large.

Approval, price and access are different things

Generic approval establishes that a product meets the regulator’s requirements for quality, safety and efficacy equivalence. It does not set the final retail price, guarantee insurance coverage or ensure that enough doses exist.

That distinction is already visible. Aspen Pharmacare received Canadian approval for a generic Ozempic version, but said its launch depends on supplies of the active pharmaceutical ingredient from Dr. Reddy’s Laboratories. Dr. Reddy’s has reported disruption after an impurity issue halted new production, with normalization expected no earlier than late October.

Health Canada notes that generic medicines in the country are often 45% to 90% cheaper than branded products. The exact discount for semaglutide will depend on competition, negotiated reimbursement, manufacturing capacity and the delivery devices used.

What happens next

The decisive evidence will come from pharmacies and public drug plans: actual prices, reliable supply, changes in reimbursement and whether appropriate patients remain on treatment. Competition may also reveal whether the injector pen, manufacturing capacity and distribution network are as important as the molecule itself.

Generic semaglutide could turn a celebrated drug into a more broadly usable health tool. Canada’s experience will show whether patent expiry produces real access, or merely a longer list of approved products that many patients still cannot obtain.